


Attorney Docket No. NASH-001/03US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 4, 2003.



By: 
Vladimir Skliba

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Thomas M. VAUGHN et al.

Examiner:

Unassigned

Serial No.: 10/601,314

Art Unit:

1614

Filed: June 20, 2003

Confirmation No.:

6959

For: METHODS OF MAKING AND USING THEAFLAVIN, THEAFLAVIN-3-GALLATE, THEAFLAVIN-3'-GALLATE AND THEAFLAVIN 3,3'-DIGALLATE AND MIXTURES THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Transmitted herewith are:

1. Information Disclosure Statement under 37 CFR §1.97(b)
2. PTO/SB/08A
3. PCT Search Report
4. 8 references (A4-A10 and B1)
5. Return receipt postcard


In accordance with 37 C.F.R. §1.97(b), no fee for submission of the IDS is required.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: November 4, 2003

Respectfully submitted,
COOLEY GODWARD LLP

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663

By: 
Sunil K. Singh
Reg. No. 45,298

This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: November 4, 2003

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000
Fax: (650) 857-0663


Respectfully submitted,
COOLEY GODWARD LLP

By:



Sunil K. Singh
Reg. No. 45,298

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/601,314
				Filing Date	June 20, 2003
				First Named Inventor	Thomas M. VAUGHN
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	NASH-001/03US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	ALDERMAN D. A., "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech. Prod. Mfr.</i> 5(3):1-9, 1984		
	C2	BAMBA et al., "Release mechanisms in gelforming sustained release preparations," <i>Int. J. Pharm.</i> 2:307, 1979		
	C3	BERGE et al., <i>J. Pharm. Sci.</i> 66:1-19, 1977		
	C4	LEUNG et al., "Theaflavins in Black Tea and Catechins in Green Tea Are Equally Effective Antioxidants," <i>J. Nutr.</i> 131(9):2248-2251, 2001		
	C5	SARKAR et al., <i>Biochem. Biophys. Res. Commun.</i> 284(1):173-178, 2001		
	C6	VERMA et al., <i>Drug Dev. Ind. Pharm.</i> 26:695-708, 2000		
	C7	YOSHINO et al., <i>Biol. Pharm. Bull.</i> 17(1):146-149, 1994		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.